Design Therapeutics, Inc. (DSGN) vs Solid Biosciences Inc. (SLDB)

Design Therapeutics, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Solid Biosciences Inc. are of similar size ($809.3M and $802.0M). Across the 10 metrics below, Design Therapeutics, Inc. leads on 5 and Solid Biosciences Inc. on 5.

Valuation

Metric DSGN SLDB Biotechnology median
P/E n/m n/m 7.88
P/S 3,363.10 93.13 11.47
P/B 3.77 2.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2,445.42 59.52 10.73
Earnings yield (9.70%) (26.20%) (28.84%)
Free cash flow yield (7.27%) (17.92%) (23.03%)

Profitability

Metric DSGN SLDB Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (34.13%) (65.50%) (57.72%)
Return on assets (32.33%) (56.83%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DSGN SLDB Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (38.64%) 34.97% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.86 13.82 4.73
Net debt to EBITDA 2.68 1.05 0.96

Dividend

Metric DSGN SLDB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DSGN SLDB Biotechnology median
Market cap 809.26m 802.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack